Ghost Tree Capital, LLC Altimmune, Inc. Transaction History

Ghost Tree Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $2.06 Million - $3.45 Million	250,000 New	250,000 $2.55 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $4.64 Million - $9.75 Million	435,000 New	435,000 $5.56 Million
Q4 2020 Feb 16, 2021	SELL	$7.84 - $14.22 $1.57 Million - $2.84 Million	-200,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$9.93 - $33.26 $496,500 - $1.66 Million	50,000 Added 33.33%	200,000 $2.64 Million
Q2 2020 Aug 14, 2020	BUY	$2.9 - $10.71 $435,000 - $1.61 Million	150,000 New	150,000 $1.61 Million

190

42.2M

1.05M

582K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $366M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Ghost Tree Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ghost Tree Capital, LLC with notifications on news.